Pharmaceutical giant Eli Lilly has hit the headlines after company’s Chairman and CEO Dave Ricks publicized the launch of an affordable version of Humalog, its rapid-acting insulin brand. Eli …
The latest results indicate a promising risk-benefit profile in all pemphigus patients Principia Biopharma now intends to confirm these results through the current Phase 3 PEGASUS study Principia Biopharma …
In accordance with the preliminary results, the company looks forward to a Phase 2 trial by this year’s third quarter, in kids with achondroplasia. Ascendis Pharma A/S, the Denmark-based, …
CureVac’s vaccine platform has the potential to improve CEPI’s ability to respond to the emerging Disease X, claims CEPI CEO. In a move to defeat the next pandemic, the …
Lynparza was the first PARP drug to reach the market after it was approved for ovarian cancer in U.S. Leading multinational pharmaceutical and biopharmaceutical firm, AstraZeneca Plc., has recently …
The U.S. Food & Drug Administration (FDA) has reportedly approved TAS-102 (trifluridine/tipiracil; Lonsurf, Taiho Oncology) for the treatment of adult patients afflicted with metastatic GEJ (gastroesophageal junction) adenocarcinoma. Reportedly, …
Eyenovia, Inc., has reportedly declared attaining positive results from its second MicroStat Phase III study, known as MIST-2. If reports are to be believed this study evaluated the efficacy …
The drug has been specifically developed for the nonalcoholic fatty liver disease (NASH) The clinical trial is expected to report by the third quarter of 2019 Boehringer Ingelheim (Boehringer), …
The drug failed to meet primary endpoint of lessening the number of binging days right from the starting point to the eighth week Opiant Pharmaceuticals Inc., a US-based specialty …
Agios Pharmaceuticals, Inc. has recently announced that the FDA has accepted the supplemental New Drug Application (sNDA) of the company for TIBSOVO®. Apparently, the drug would be used in …
